Oligonucleotide in Medical Technology

Another LNA-based RNA Inhibitor Enters Clinical Trials

... LNA-based PIK3CA antagonist" "EZN-3042, a novel locked nucleic acid oligonucleotide against survivin, inhibits survivin expression and confers taxol sensitivity" "EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling ...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. About SEQUENOM SEQUENOM is a life sciences company committed to providing the best genetic analysis products that ...

Quark Pharmaceuticals Presents at Asia TIDES Conference

... Ph.D., Vice President, Pharmaceutical Development presented an overview of Quark's novel pipeline of synthetic siRNA compounds at the Asia TIDES oligonucleotide and Peptide(R) Technology and Product Development Conference, held February 24th, 2009 in Tokyo, Japan. Dr. Thompson's presentation, entitled ...

ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis

... provide login details on its website http://www.antisense.com.au once these are confirmed. Conference abstract follows: VLA-4 Antisense - An oligonucleotide targeting VLA-4 mRNA (ATL1102) significantly reduces new active lesions in patients with RR-MS Volker Limmroth(1), Frederik Barkhof(2), Nuket ...

Genta Clinical Programs Featured at American Society of Hematology Meeting

... featured press briefing sponsored by ASH on Sunday December 9 at 9:30 am. -- Oblimersen (Genasense(R)), a phosphorothioate Bcl-2 antisense oligonucleotide (ASO), can be safely administered by bolus subcutaneous (SC) injection and brief IV Infusion. Publication. -- Phase 1 assessment of G4544, an ...

Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

The Past, Present and Future of HLA Typing

... either by hybridizing labeled, sequence specific oligonucleotide probes to HLA loci amplified by the polymerase ... hybridize it with a labeled, sequence specific oligonucleotide probe. The original methods, described in the ... with radioactively labeled, sequence specific oligonucleotide probes. These probes would bind only to ...

Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity

... School of Medicine and a senior author of the publication. "Alnylam's research on miRNAs derives from our discovery of antagomirs, a novel class of oligonucleotide inhibitors of miRNAs. These reagents have become powerful tools to investigate the role of miRNAs in biology and disease processes. We are fortunate ...

Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The lead drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the ...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection

... (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in ...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

... essential for malignant cell growth and absent or expressed transiently at low levels in most normal adult tissues. GRN163L is a short chain oligonucleotide that is unique in its resistance to nuclease digestion in blood and tissues and its very high affinity and specificity for telomerase. The molecule ...